血栓形成倾向增高与慢性肢体威胁性缺血患者血运重建结局相关
本研究纳入34例慢性肢体威胁性缺血(CLTI)患者和62例非CLTI患者,在血管内治疗(EVT)当日用全血栓形成分析系统(T-TAS)检测血栓形成倾向。中位随访574天,CLTI组10例(29%)、非CLTI组11例(18%)发生临床驱动的靶病变血运重建(CD-TLR)。在CLTI组,发生CD-TLR者AR10-AUC30高于未发生者(中位1694 vs 1561,P=0.01),且AR10-AUC30是CD-TLR的独立预测因子(每增加100单位,HR 2.04,95%CI 1.18-3.88,P=0.01);非CLTI组无显著关联。结论认为AR10-AUC30在CLTI患者中有预测CD-TLR的潜力,高凝状态可能起主要作用,抗凝治疗可能有助于预防血运重建。
要点
- CLTI患者EVT后CD-TLR发生率为29%,非CLTI患者为18%。
- CLTI组发生CD-TLR者AR10-AUC30中位1694,高于未发生者的1561(P=0.01)。
- CLTI患者AR10-AUC30每增加100单位,CD-TLR风险HR 2.04(95%CI 1.18-3.88,P=0.01)。
核心结论
- 在CLTI患者中(而非非CLTI患者),AR10-AUC30显示出预测CD-TLR的潜力。
- 该发现提示高凝状态可能在CLTI进展中起主要作用,抗凝治疗可能有助于预防血运重建。
研究设计与样本
- 研究分析了34例CLTI患者和62例非CLTI患者,均接受EVT。
- EVT当日采血,用T-TAS计算血小板芯片在24 μL/min流速下前10分钟的血栓形成面积AUC(PL24-AUC10)和动脉粥样硬化芯片在10 μL/min流速下前30分钟的AUC(AR10-AUC30)。
- EVT后临床随访评估CD-TLR,中位随访574天。
主要发现
- 随访期间CLTI组10例(29%)和非CLTI组11例(18%)发生CD-TLR。
- CLTI组发生CD-TLR者AR10-AUC30中位1694(IQR 1657-1799),高于未发生者的中位1561(IQR 1412-1697),P=0.01。
- PL24-AUC10在两组中按CD-TLR分层均无显著差异。
- CLTI患者多变量Cox回归(倾向评分匹配)显示AR10-AUC30是CD-TLR的独立预测因子(每增加100单位,HR 2.04,95%CI 1.18-3.88,P=0.01),已调整基线人口学、病变特征和抗凝药使用。
- 非CLTI患者中AR10-AUC30和PL24-AUC10均与CD-TLR无显著关联。
关键数值与推荐
- CLTI组发生CD-TLR者AR10-AUC30中位1694(IQR 1657-1799) vs 未发生者中位1561(IQR 1412-1697),P=0.01。
- CLTI患者AR10-AUC30每增加100单位,CD-TLR的HR 2.04(95%CI 1.18-3.88,P=0.01)。
- AR10-AUC30预测CD-TLR的最佳截断值为1646,AUC 0.85,敏感性0.93,特异性0.56。
临床怎么用
- 作者认为,对于CLTI患者,AR10-AUC30显示出预测CD-TLR的潜力。
- 作者提出,高凝状态可能在CLTI进展中起主要作用,抗凝治疗可能有助于预防血运重建。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Clinically driven target lesion revascularization (CD-TLR) frequently occurs after endovascular therapy (EVT) in patients with chronic limb-threatening ischemia (CLTI). The total thrombus-formation analysis system (T-TAS) can quantitatively evaluate thrombogenicity. Therefore, we aimed to elucidate the association of the T-TAS parameters with CD-TLR. METHODS: We analyzed 34 patients with CLTI and 62 patients without CLTI who had undergone EVT. Blood samples collected on the day of EVT were used in the T-TAS to compute the thrombus formation area under the curve for the first 10 minutes for the platelet chip tested at a flow rate of 24 μL/min (PL24-AUC10) and area under the curve for the first 30 minutes for the atheroma chip tested at a flow rate of 10 μL/min (AR10-AUC30). After EVT, clinical follow-up was performed, and the presence of CD-TLR was assessed. RESULTS: During the follow-up period (median, 574 days), 10 patients (29%) in the CLTI group and 11 (18%) in the non-CLTI group had required CD-TLR. In the CLTI group, the patients with CD-TLR had had a higher AR10-AUC30 vs those without (median, 1694 [interquartile range, 1657-1799] vs median, 1561 [interquartile range, 1412-1697]; P = .01). In contrast, the PL24-AUC10 showed no significant differences when stratified by CD-TLR in either group. For the CLTI patients, multivariable Cox regression analysis using propensity score matching revealed that the AR10-AUC30 was an independent predictor of CD-TLR even after adjusting for baseline demographics, lesion characteristics, and anticoagulant use (hazard ratio, 2.04; 95% confidence interval, 1.18-3.88; P = .01; per 100-unit increase). In contrast, for those without CLTI, neither the AR10-AUC30 nor the PL24-AUC10 was significantly associated with CD-TLR. Receiver operating characteristics curve analysis identified an AR10-AUC30 level of 1646 as an optimal cutoff value to predict for CD-TLR (AUC, 0.85; sensitivity, 0.93; specificity, 0.56). CONCLUSIONS: For patients with CLTI, but not for those without CLTI, the AR10-AUC30 showed potential to predict for CD-TLR. This finding suggests that hypercoagulability might play a predominant role in the progression of CLTI and that anticoagulant therapy might be useful in preventing revascularization.
引用
- Kuyama N, Kaikita K, Ishii M, et al. Increased thrombogenicity is associated with revascularization outcomes in patients with chronic limb-threatening ischemia. J Vasc Surg. 2022. PMID: 35390483. doi:10.1016/j.jvs.2022.03.874
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。